This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| CD80 | |
|---|---|
| Name | CD80 |
| Alt | B7-1 |
| Uniprot | P33681 |
| Organism | Homo sapiens |
CD80 CD80 is a cell surface glycoprotein of the B7 family that provides critical costimulatory signals for adaptive immunity. It interacts with receptors on T lymphocytes to influence activation, tolerance, and effector differentiation, and has been studied across immunology, oncology, and transplantation contexts. Research spans molecular biology, clinical trials, and biopharmaceutical development involving prominent institutions and investigators.
CD80 is encoded by a gene located on human chromosome 3 and belongs to the immunoglobulin superfamily; structural studies have used crystallography and electron microscopy to define its extracellular Ig-like V and C domains. High-resolution structures were solved with techniques favored by laboratories associated with Nobel laureates in structural biology and have informed engineering efforts by biotechnology companies and university spin-offs. The gene architecture and promoter elements were compared in comparative genomics projects involving model organisms such as Mus musculus, Rattus norvegicus, and Macaca mulatta, and sequence variation has been catalogued by consortia including the Human Genome Project and the 1000 Genomes Project.
CD80 expression is inducible on antigen-presenting cells including dendritic cells, macrophages, and B cells after stimulation by microbial products, cytokines, or cell contact signals; these induction pathways have been characterized in studies involving Toll-like receptor agonists, interferons studied by labs tied to the Pasteur Institute and the Rockefeller University, and inflammasome pathways investigated alongside research from the National Institutes of Health. Transcriptional regulators and epigenetic modifiers identified in work associated with major research centers such as Harvard Medical School and University of Cambridge modulate CD80 levels, while post-translational modifications and trafficking involve machinery characterized in cell biology programs at institutions like the Max Planck Society.
CD80 binds to T cell receptors CD28 and CTLA-4 to deliver costimulatory and coinhibitory signals that determine T cell fate; foundational immunology work from laboratories linked to the Duke University and the Salk Institute defined these interactions. These receptor-ligand dynamics have been analyzed in contexts such as alloreactivity in transplantation research at the Mayo Clinic, antitumor immunity in oncology centers including Memorial Sloan Kettering Cancer Center, and tolerance mechanisms explored by groups at the Fred Hutchinson Cancer Center. Animal models like those developed at Stanford University and comparative studies involving Gallus gallus and Canis lupus familiaris have clarified roles in cytotoxic T lymphocyte activation, regulatory T cell induction, and B cell help.
Aberrant CD80 expression or signaling contributes to autoimmune diseases, cancer immune evasion, and chronic infectious disease pathology; clinical associations have been reported by collaborative networks including the European League Against Rheumatism and the American Society of Clinical Oncology. In autoimmunity, cohorts studied at tertiary centers such as Johns Hopkins Hospital and Cleveland Clinic revealed correlations with disease activity in conditions investigated by consortia like the International Multiple Sclerosis Genetics Consortium. In oncology, tumor microenvironment studies from institutions like University of Texas MD Anderson Cancer Center and pharmaceutical partnerships have examined CD80 modulation by oncogenic pathways characterized in research traced to the Wellcome Trust. Infectious disease research at organizations such as the Centers for Disease Control and Prevention linked pathogen-mediated modulation of CD80 to chronicity and immune escape.
Therapeutic strategies targeting the CD80 axis include fusion proteins, monoclonal antibodies, and CAR-T cell designs developed by biotech firms and academic spin-outs from institutions like University of Pennsylvania and Yale University. CTLA-4–Ig fusion biologics and checkpoint inhibitors informed by trials coordinated by groups associated with the Food and Drug Administration and large cooperative groups have reshaped treatment of malignancies overseen by organizations such as European Society for Medical Oncology. Transplant tolerance protocols and autoimmune disease interventions studied in randomized trials at centers including Karolinska Institutet and Imperial College London examine modulation of CD80-mediated pathways. Vaccine adjuvant research leveraging CD80 induction has been pursued in collaborations involving the Bill & Melinda Gates Foundation and public-private consortia.
Detection and quantification of CD80 employ flow cytometry panels standardized in clinical immunology labs at institutions like St. Jude Children's Research Hospital and Vanderbilt University Medical Center, immunohistochemistry used in pathology departments at university hospitals, and ELISA assays developed by commercial suppliers with validation in multicenter studies. Functional assays include mixed lymphocyte reactions, T cell proliferation assays, and synapse imaging using microscopy platforms produced by companies with ties to academic cores at Massachusetts Institute of Technology and ETH Zurich. Genetic manipulation using CRISPR workflows and transgenic mouse strains hosted by repositories such as the Jackson Laboratory enable mechanistic dissection, while systems immunology approaches integrate data from consortia like the Human Cell Atlas.
Category:Immune system proteins